Susquehanna International Group, LLP Silverback Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	N/A	-821,300 Reduced 81.69%	184,100 $0
Q2 2024 Aug 15, 2024	BUY	N/A	779,800 Added 345.66%	1,005,400 $0
Q1 2024 May 07, 2024	BUY	N/A	193,300 Added 598.45%	225,600 $0
Q4 2023 Feb 14, 2024	SELL	N/A	-81,000 Reduced 71.49%	32,300 $0
Q3 2023 Nov 14, 2023	BUY	N/A	113,300 New	113,300 $0
Q1 2023 May 16, 2023	BUY	N/A	13,400 Added 6.88%	208,200 $0
Q4 2022 Feb 14, 2023	BUY	$0.0 - $6.07 $0 - $185,135	30,500 Added 18.56%	194,800 $0
Q3 2022 Nov 14, 2022	BUY	$3.91 - $5.52 $150,926 - $213,071	38,600 Added 30.71%	164,300 $868,000
Q2 2022 Aug 15, 2022	BUY	$2.9 - $4.44 $244,470 - $374,292	84,300 Added 203.62%	125,700 $533,000
Q1 2022 May 16, 2022	SELL	$3.51 - $6.74 $68,796 - $132,104	-19,600 Reduced 32.13%	41,400 $145,000
Q4 2021 Feb 14, 2022	BUY	$6.03 - $11.67 $367,830 - $711,870	61,000 New	61,000 $406,000

163

62.7M

872K

589K

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.